Gram-Negative Bacterial Infection Therapeutics Market, Global Outlook and Forecast 2022-2028

March 2022 | 66 pages | ID: GF8F2E759EC0EN
Market Monitor Global

Abstracts

Gram-negative bacteria generally refer to bacteria that show red in the gram-negative staining reaction.

This report contains market size and forecasts of Gram-Negative Bacterial Infection Therapeutics in Global, including the following market information:

Global Gram-Negative Bacterial Infection Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Gram-Negative Bacterial Infection Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Enteral Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gram-Negative Bacterial Infection Therapeutics include Baxter, Sanofi, GlaxoSmithKline, Novartis, Pfizer, Takeda, Nektar Therapeutics, Sumitomo and Targeted Genetics. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gram-Negative Bacterial Infection Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gram-Negative Bacterial Infection Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Gram-Negative Bacterial Infection Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Enteral Treatment
• Parenteral Treatment
• Topical Treatment

Global Gram-Negative Bacterial Infection Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Gram-Negative Bacterial Infection Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Others

Global Gram-Negative Bacterial Infection Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Gram-Negative Bacterial Infection Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Gram-Negative Bacterial Infection Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Gram-Negative Bacterial Infection Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Baxter
• Sanofi
• GlaxoSmithKline
• Novartis
• Pfizer
• Takeda
• Nektar Therapeutics
• Sumitomo
• Targeted Genetics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Gram-Negative Bacterial Infection Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Gram-Negative Bacterial Infection Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL GRAM-NEGATIVE BACTERIAL INFECTION THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size: 2021 VS 2028
2.2 Global Gram-Negative Bacterial Infection Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Gram-Negative Bacterial Infection Therapeutics Players in Global Market
3.2 Top Global Gram-Negative Bacterial Infection Therapeutics Companies Ranked by Revenue
3.3 Global Gram-Negative Bacterial Infection Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Gram-Negative Bacterial Infection Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Gram-Negative Bacterial Infection Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gram-Negative Bacterial Infection Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Gram-Negative Bacterial Infection Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Gram-Negative Bacterial Infection Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Gram-Negative Bacterial Infection Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Enteral Treatment
  4.1.3 Parenteral Treatment
  4.1.4 Topical Treatment
4.2 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Gram-Negative Bacterial Infection Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Others
5.2 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Gram-Negative Bacterial Infection Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
  6.3.2 US Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.3.3 Canada Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
  6.4.2 Germany Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.4.3 France Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.4.5 Italy Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.4.6 Russia Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
  6.5.2 China Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.5.3 Japan Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.5.6 India Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.7.3 Israel Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
  6.7.5 UAE Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Baxter
  7.1.1 Baxter Corporate Summary
  7.1.2 Baxter Business Overview
  7.1.3 Baxter Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.1.4 Baxter Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Baxter Key News
7.2 Sanofi
  7.2.1 Sanofi Corporate Summary
  7.2.2 Sanofi Business Overview
  7.2.3 Sanofi Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.2.4 Sanofi Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Sanofi Key News
7.3 GlaxoSmithKline
  7.3.1 GlaxoSmithKline Corporate Summary
  7.3.2 GlaxoSmithKline Business Overview
  7.3.3 GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.3.4 GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 GlaxoSmithKline Key News
7.4 Novartis
  7.4.1 Novartis Corporate Summary
  7.4.2 Novartis Business Overview
  7.4.3 Novartis Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.4.4 Novartis Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Novartis Key News
7.5 Pfizer
  7.5.1 Pfizer Corporate Summary
  7.5.2 Pfizer Business Overview
  7.5.3 Pfizer Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.5.4 Pfizer Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Pfizer Key News
7.6 Takeda
  7.6.1 Takeda Corporate Summary
  7.6.2 Takeda Business Overview
  7.6.3 Takeda Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.6.4 Takeda Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Takeda Key News
7.7 Nektar Therapeutics
  7.7.1 Nektar Therapeutics Corporate Summary
  7.7.2 Nektar Therapeutics Business Overview
  7.7.3 Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.7.4 Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Nektar Therapeutics Key News
7.8 Sumitomo
  7.8.1 Sumitomo Corporate Summary
  7.8.2 Sumitomo Business Overview
  7.8.3 Sumitomo Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.8.4 Sumitomo Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Sumitomo Key News
7.9 Targeted Genetics
  7.9.1 Targeted Genetics Corporate Summary
  7.9.2 Targeted Genetics Business Overview
  7.9.3 Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
  7.9.4 Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Targeted Genetics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Gram-Negative Bacterial Infection Therapeutics Market Opportunities & Trends in Global Market
Table 2. Gram-Negative Bacterial Infection Therapeutics Market Drivers in Global Market
Table 3. Gram-Negative Bacterial Infection Therapeutics Market Restraints in Global Market
Table 4. Key Players of Gram-Negative Bacterial Infection Therapeutics in Global Market
Table 5. Top Gram-Negative Bacterial Infection Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Gram-Negative Bacterial Infection Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Gram-Negative Bacterial Infection Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Gram-Negative Bacterial Infection Therapeutics Product Type
Table 9. List of Global Tier 1 Gram-Negative Bacterial Infection Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gram-Negative Bacterial Infection Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Baxter Corporate Summary
Table 31. Baxter Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 32. Baxter Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Sanofi Corporate Summary
Table 34. Sanofi Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 35. Sanofi Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 38. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Novartis Corporate Summary
Table 40. Novartis Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 41. Novartis Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 44. Pfizer Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Takeda Corporate Summary
Table 46. Takeda Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 47. Takeda Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Nektar Therapeutics Corporate Summary
Table 49. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 50. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Sumitomo Corporate Summary
Table 52. Sumitomo Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 53. Sumitomo Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Targeted Genetics Corporate Summary
Table 55. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 56. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Gram-Negative Bacterial Infection Therapeutics Segment by Type in 2021
Figure 2. Gram-Negative Bacterial Infection Therapeutics Segment by Application in 2021
Figure 3. Global Gram-Negative Bacterial Infection Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Gram-Negative Bacterial Infection Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue in 2021
Figure 8. By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Baxter Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Sanofi Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Takeda Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sumitomo Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)